Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) reveals its Competitive Advantages from the results of their research conducted at the lab at the University of Quebec at Montreal (UQAM).
Spencer reveals its competitive advantages with its oral drug applications. Spencer's technology provides a "pain free" advantage and was found to present a noticeable versatility in terms of size and characteristics (charged or uncharged, polar or non-polar, hydrophilic or not) of the therapeutic molecule to be delivered.
"It was found that our excipient was able to formulate small-size molecules either polar (hydrophilic such as metformin or ibuprofen) or non polar (as acetaminophen) as well as medium or large-size molecules such as bioactive peptides (ex. Nisin), proteins or even microorganisms (probiotics), essentially applying to many popular Over the Counter drugs and prescribed as well," stated Dr. Max Arella, CEO of the company.
However many of the delivery technologies for therapeutic peptides or proteins failed to overcome three major obstacles: i) Denaturation of the peptide or of the protein or bacterium by gastric acid and even by pepsin protease in the stomach environment, ii) Degradation of the peptide or protein or bacterium by the attack of proteolytic enzymes in intestine, iii) poor or limited absorption of the peptide or protein into the bloodstream (if not directed to the colon).
Spencer's matrix is versatile, but also affords a gastro-protection against acidity and proteolysis, particularly in the case of sensitive bioactive agents (peptides, proteins, bacteria) contributing thus to their stability during the gastric and intestinal transit. In addition, it possesses the muco-adhesive properties which can prevent proteolysis and enhance their intestinal mucosal retention or uptake to the bloodstream in an active form.
No comments:
Post a Comment